Hoth Therapeutics Reports 100% Clinical Response in EGFR Cancer Trial
Event summary
- Hoth Therapeutics reported 100% clinical response in the open-label PK cohort of its CLEER-001 trial evaluating HT-001 in EGFR-treated cancer patients.
- Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease.
- Additional endpoints showed ~34% improvement in oncology toxicity (CTCAE) and ~37% reduction in patient-reported pruritus.
- HT-001 was well tolerated with no unexpected safety signals observed.
The big picture
Hoth Therapeutics' positive interim results from the CLEER-001 trial highlight the potential of HT-001 as a supportive-care therapy for cancer patients receiving EGFR inhibitors. This addresses a significant unmet need in managing treatment-related toxicity and symptom burden, which often impacts treatment continuity and outcomes. The results position HT-001 as a promising candidate in the oncology supportive-care space, potentially improving patient quality of life and treatment adherence.
What we're watching
- Clinical Validation
- Whether HT-001 can sustain these results in larger, controlled trials.
- Regulatory Pathway
- The pace at which Hoth Therapeutics advances HT-001 through regulatory approvals.
- Market Potential
- How HT-001's supportive-care therapy could impact the oncology market.
Related topics